High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.
about
The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpointsRole of the tumor microenvironment in mature B-cell lymphoid malignanciesHigh-dimensional single-cell cancer biologyNew antibody approaches to lymphoma therapyElevated monocyte phosphorylated p38 in nearby employees after a chemical explosionProgrammed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for SepsisThe clinical development of obinutuzumab for the treatment of follicular lymphoma.Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.Immune checkpoint blockade for hematologic malignancies: a reviewSafety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survivalCD10 delineates a subset of human IL-4 producing follicular helper T cells involved in the survival of follicular lymphoma B cellsSeveral immune escape patterns in non-Hodgkin's lymphomas.Microenvironment abnormalities and lymphomagenesis: Immunological aspects.Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.Inhibitory receptor expression on memory CD8 T cells following Ad vector immunization.Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer.Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.Chemotherapy-free treatment in patients with follicular lymphoma.Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system.Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas.Immune checkpoint blockade in lymphoid malignancies.Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.Challenges in vaccine therapy in hematological malignancies and strategies to overcome them.Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015.Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma.Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma.Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.Expression of programmed death-1 (CD279) in primary cutaneous B-cell lymphomas with correlation to lymphoma entities and biological behaviour.
P2860
Q26745842-78BE130E-72CB-4A6F-A7D4-B4D2D0C78E83Q26748775-536ED174-332E-4FA4-90C7-5E19B627920AQ27021173-B6758131-DF9C-41F0-9433-486AEE2AAFDFQ27022373-4AA7B121-3B9B-40F7-A96C-2E56E4EAF849Q28831248-41634792-D470-4FA1-99D6-00C8EB1A5E52Q29994668-97D38039-A73B-4195-BACE-E6E7C7BA2E50Q33565265-3223ED38-3C3B-45C4-9A2F-75D0C9C34A82Q33638083-BC775AA5-C443-4287-A0A3-1400DED19B44Q33645590-AFAB0DC4-33AA-4E8A-8604-DF2485B05E49Q34391446-57F9D5CB-96BF-462B-B8AA-6A9ECE1355B8Q35056309-B6BBCAEB-3A84-4642-89B1-A015A9FCF494Q35146249-00C73F50-56CE-489C-B455-2CDE8C1073D4Q35460668-6DB91154-85EF-4EEE-BBBF-FAEC044339D6Q36060357-9A83E5F3-C7B7-48B6-BF2A-DE68C65721CEQ36118020-35B1D4F0-3B11-467E-BECA-561158640FE6Q36522770-AC5F25C9-1B84-47B1-AB79-D941FF8E53E5Q37287424-451FA7BB-2DAB-4E2B-A90B-BD5BEB6C3B57Q37562562-74BAECE1-4059-4961-BBD7-9128A73ED9D7Q37641801-4D2D767F-D70C-47A6-B1A9-6ED26ED6DAE8Q38108353-A3AC8768-342E-44FE-BAB8-9E42AD60D3BFQ38155039-B8E893B7-E8DF-467A-B4C1-461FFED54B86Q38174058-A2DFF88C-8867-4E01-A20B-CA3DD8109F89Q38317235-6FF3F78E-73F5-4A85-AAD1-227CEFE6DE33Q38489700-A3C903F5-C9D6-4381-BFE9-4ABBD369E7B7Q38637599-84F142C8-63A5-4F17-99CA-3DCF9E1B81EEQ38710672-187C58EB-DE10-432C-9A38-5AEAB874FE71Q38799409-1C61C823-658F-49B9-9CC4-A2874C9FF48BQ38843235-38633BD9-86F1-4766-846F-7A36979158D2Q38844205-F79A0E27-FB6D-41F1-BA35-D492DC317F00Q38996724-DEC06892-2037-478A-B575-3386E6EA1243Q39043404-4A2A1E35-405C-4D29-8BB8-12BA8C7C1E50Q39221094-F377FEE1-B48C-4D33-A0CC-EAF91E6FE75EQ39237785-920B57E3-30CF-41CC-B052-DC6B1126F490Q39420466-C01CFE08-3304-43D1-AF7F-F2A51CDB332EQ39706167-4A3AEB4F-3E7E-4D3B-BFCF-8B034873C679Q40483712-CB0913A8-B711-4763-9078-64A00C223DF4Q40971062-A8B4D319-FC06-443C-814E-49DB86CDA82BQ41578214-A32CE391-30BC-4785-95EB-70522F8B9B22Q42503470-0AF7B69E-1BE2-420A-8D59-477DE82DD886Q45022238-20534C61-4F8B-4F22-B61F-9073EF0BA2EA
P2860
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
High PD-1 expression and suppr ...... umors from peripheral T cells.
@ast
High PD-1 expression and suppr ...... umors from peripheral T cells.
@en
type
label
High PD-1 expression and suppr ...... umors from peripheral T cells.
@ast
High PD-1 expression and suppr ...... umors from peripheral T cells.
@en
prefLabel
High PD-1 expression and suppr ...... umors from peripheral T cells.
@ast
High PD-1 expression and suppr ...... umors from peripheral T cells.
@en
P2093
P2860
P50
P1433
P1476
High PD-1 expression and suppr ...... tumors from peripheral T cells
@en
P2093
Arne Kolstad
Debra K Czerwinski
Holbrook E Kohrt
John Timmerman
Jonathan Said
Joshua Brody
June H Myklebust
Roch Houot
Ronald Levy
P2860
P304
P356
10.1182/BLOOD-2012-04-421826
P407
P577
2013-01-07T00:00:00Z